滤泡性淋巴瘤进展相关突变在诊断时预测较差结局:Alliance A151303研究
该研究对370例滤泡性淋巴瘤(FL)或转化型FL患者进行临床基因组分析,发现诊断时携带进展相关突变(MAP)特征(7个基因中≥2个突变)的患者一线无进展生存期更短,该7基因集对进展风险的预测可能比m7-FLIPI更具普遍适用性。
要点
- 诊断时FL携带MAP特征(7基因中≥2个突变)与更短的一线无进展生存期相关。
- CREBBP是FL中较t-FL更常见突变的唯一基因,且突变与FL更短一线PFS相关。
- 复发/难治FL和t-FL中突变负荷显著高于新诊断FL,但诊断时突变负荷与一线PFS无关。
核心结论
- 诊断时FL携带MAP特征(7个基因中≥2个突变)的患者一线无进展生存期更短,该7基因集对进展风险的预测可能比m7-FLIPI更具普遍适用性,但需未来研究验证。
研究设计与样本
- 对370例FL或t-FL患者进行临床基因组分析,样本来自癌症和白血病B组/Alliance试验50402/50701/50803或华盛顿大学医学院、克利夫兰诊所、迈阿密大学的真实世界队列。
主要发现
- 复发/难治FL和t-FL的突变负荷显著高于新诊断FL,但新诊断FL的突变负荷与一线无进展生存期无关。
- CREBBP是FL中较t-FL更常见突变的唯一基因,突变CREBBP与FL更短的一线无进展生存期相关。
- 20个基因在复发/难治FL或t-FL中较新诊断FL更常见突变,包括6个显著突变基因:STAT6、TP53、IGLL5、B2M、SOCS1和MYD88。
- 诊断时FL携带MAP特征的患者一线无进展生存期更短。
- m7-FLIPI在本队列中预后价值有限。
关键数值与推荐
- MAP特征定义为7个基因(6个复发/难治FL或t-FL显著突变基因加CREBBP)中≥2个突变。
局限性
- 原文指出未来研究需要验证诊断时FL中MAP特征相关的较差预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphoma (FL) is clinically heterogeneous, with select patients tolerating extended watch-and-wait, whereas others require prompt treatment, suffer progression of disease within 24 months of treatment (POD24), and/or experience aggressive histologic transformation (t-FL). Because our understanding of the relationship between genetic alterations in FL and patient outcomes remains limited, we conducted a clinicogenomic analysis of 370 patients with FL or t-FL (from Cancer and Leukemia Group B/Alliance trials 50402/50701/50803, or real-world cohorts from Washington University School of Medicine, Cleveland Clinic, or University of Miami). FL subsets by grade, stage, watch-and-wait, or POD24 status did not differ by mutation burden, whereas mutation burden was significantly higher in relapsed/refractory (rel/ref) FL and t-FL than in newly diagnosed (dx) FL. Nonetheless, mutation burden in dx FL was not associated with frontline progression-free survival (PFS). CREBBP was the only gene more commonly mutated in FL than in t-FL yet mutated CREBBP was associated with shorter frontline PFS in FL. Mutations in 20 genes were more common in rel/ref FL or t-FL than in dx FL, including 6 significantly mutated genes (SMGs): STAT6, TP53, IGLL5, B2M, SOCS1, and MYD88. We defined a mutations associated with progression (MAP) signature as ≥2 mutations in these 7 genes (6 rel/ref FL or t-FL SMGs plus CREBBP). Patients with dx FL possessing a MAP signature had shorter frontline PFS, revealing a 7-gene set offering insight into FL progression risk potentially more generalizable than the m7-Follicular Lymphoma International Prognostic Index (m7-FLIPI), which had modest prognostic value in our cohort. Future studies are warranted to validate the poor prognosis associated with a MAP signature in dx FL, potentially facilitating novel trials specifically in this high-risk subset of patients.
引用
- Russler-Germain DA, Krysiak K, Ramirez C, et al. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303. Blood Adv. 2023. PMID: 37493986. doi:10.1182/bloodadvances.2023010779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。